Nanometer antibody specifically combined with FAdV-4, fusion protein and application

By developing Fenobody-75, a nanoantibody that specifically binds FAdV-4, using ferritin self-assembly technology and phage display library screening, the long time and high cost of vaccine establishment in FAdV-4 infection prevention and control were solved, and efficient Simple prevention and treatment effects significantly improve poultry survival and reduce pathological damage.

CN118955698AActive Publication Date: 2024-11-15NORTHWEST A & F UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411033030.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

The prior art has problems such as long vaccine establishment time, high risk of infection during the window period and high cost of treatment drugs when preventing and controlling avian adenovirus FAdV-4 infection, and lacks comprehensive prevention and control measures that are efficient, simple and low-cost.

Method used

Fenobody-75, a nanoantibody that specifically binds FAdV-4, was developed, and was prepared by ferritin self-assembly technology. The phage display library was used to screen nanoantibody anti-FAdV-4 fibromidein 2 to form multimerized antibodies to achieve Effective prevention and treatment of FAdV-4.

Benefits of technology

Fenobody-75 expression is simple to purify, stable traits, low production cost, good antiviral effects, can effectively prevent and treat FAdV-4 infection, significantly improve the survival rate of poultry and reduce pathological damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955698A_ABST
    Figure CN118955698A_ABST
Patent Text Reader

Abstract

The invention discloses a nano antibody specifically combined with FAdV-4, fusion protein and application, and belongs to the technical field of veterinary biological products. According to the invention, on the basis of a phage nano antibody display library of FAdV-4, a specific nano antibody for resisting FAdV-4 spike protein 2 (Fiber 2) is screened, and the nano antibody is subjected to genetic engineering modification and expression by utilizing a self-assembly technology of ferritin to prepare the multimerization nano antibody Finobody-75 for resisting FAdV-4. The antibody is simple in expression and purification, stable in character and low in production cost. The antiviral effect is analyzed through in-vitro and in-vivo tests. The result shows that the Fanbody-75 disclosed by the invention is high in safety and has a good protection effect on FAdV-4 infection. Therefore, as the biological preparation for resisting FAdV-4 infection of poultry, the Fenody-75 has a very good market application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of veterinary biological products, and in particular to a nano antibody specifically binding to FAdV-4, a fusion protein and an application thereof. Background Art

[0002] Fowl adenovirus (FAdV) belongs to the genus Adenovirus of the family Adenoviridae and can infect poultry such as chickens, turkeys, geese, ducks, pheasants and quails. FAdV is prevalent worldwide, causing huge economic losses to the poultry industry. FAdV infection can cause a variety of clinical diseases, including inclusion body hepatitis (IBH), hydropericardium hepatitis syndrome (HHS), gizzard erosions (GE), etc. At present, the prevalent serotypes are mainly serotype 4 (FAdV-4), serotype 8 (FAdV-8) and serotype 11 (FAdV-11), among which FAdV-4 is the most prevalent.

[0003] At present, the prevention and control of FAdV-4 infection is mainly based on vaccine immunization. After vaccination, it generally takes at least 7 days to establish the immune effect, and there is a possibility of infection with FAdV-4 during the window period. In addition, once an outbreak of FAdV-4 occurs in a chicken farm that has not been vaccinated, the disease will spread rapidly, and the chickens will gradually become ill or even die within 3-10 days. At this time, the emergency immunization vaccine cannot effectively protect the chickens in a timely manner. In this case, an effective treatment method is an important measure to reduce losses. It is well known that yolk antibodies have a wide market application in the field of poultry disease prevention and control. Among them, there are approved veterinary yolk antibodies on the market for many avian viral diseases such as duck hepatitis, goose plague, and infectious bursal disease. At present, there have been many studies on FAdV-4 yolk antibodies, all of which have shown good preventive and therapeutic effects against homologous strains. However, the preparation cost of yolk antibodies is relatively high and has high requirements on the health of laying hens. Therefore, other specific drugs that are efficient, easy to prepare, and low in cost are of great significance for the comprehensive prevention and control of FAdV-4.

[0004] Nanobodies, as the third generation of genetically engineered antibodies, are the smallest antibodies known to have antigen-binding ability. Compared with traditional monoclonal antibodies, their molecular weight is only about 15kDa. In addition, this type of antibody is easy to genetically engineer and can be coupled with a variety of fragments; it is also easy to express and purify, and can be expressed using Escherichia coli expression systems, yeast expression systems, mammalian cells or plant cells. Therefore, as a therapeutic drug, nanobodies have the advantages of good specificity and stability, simple production process and low production cost. Therefore, the development of efficient, easy-to-prepare and low-cost nanoantibody drugs is crucial for the comprehensive prevention and control of FAdV-4. Summary of the invention

[0005] The purpose of the present invention is to provide a nano antibody, a fusion protein and an application that specifically binds to FAdV-4 to solve the problems existing in the above-mentioned prior art.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] One of the technical solutions of the present invention is a nanobody that specifically binds to FAdV-4, and its amino acid sequence is as shown in SEQ ID Shown in NO.3.

[0008] The second technical solution of the present invention is a DNA molecule encoding the nanobody, whose nucleotide sequence is shown in SEQ ID NO.4.

[0009] The third technical solution of the present invention is a fusion protein, whose amino acid sequence is as shown in SEQ ID Shown in NO.1.

[0010] The fourth technical solution of the present invention is a DNA molecule encoding the fusion protein, and its nucleotide sequence is shown as SEQ ID NO.2.

[0011] The fifth technical solution of the present invention is a recombinant expression vector, comprising the above-mentioned DNA molecule.

[0012] The sixth technical solution of the present invention is the use of the nanobody, the fusion protein or the recombinant expression vector in the preparation of a drug for preventing and treating FAdV-4 infection.

[0013] The seventh technical solution of the present invention is a drug for preventing and treating FAdV-4 infection, comprising the nanoantibody or the fusion protein.

[0014] Based on the above technical solution, the present invention has the following technical effects:

[0015] The present invention is based on the phage nanoantibody display library of FAdV-4, screens specific nanoantibodies against FAdV-4 fiber protein 2 (Fiber 2), and uses the self-assembly technology of ferritin to genetically engineer the nanoantibodies to express and prepare the anti-FAdV-4 polymerized nanoantibody Fenobody-75. The antibody is simple to express and purify, has stable properties, and has low production costs. The antiviral effect was analyzed by in vitro and in vivo tests. The results show that the Fenobody-75 of the present invention is highly safe and has a good protective effect against FAdV-4 infection. Therefore, Fenobody-75 has a good market application prospect as a biological agent for resisting FAdV-4 infection of poultry. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0017] Figure 1 is the titer of anti-FAdV-4 antibodies in the serum after the fifth immunization of Bactrian camels;

[0018] Figure 2 To obtain lymphocytes from the peripheral blood of immune Bactrian camels by separating them with Ficoll lymphocyte separation medium;

[0019] Figure 3 The first round of PCR amplification of the nanoantibody gene product by nested PCR was analyzed by agarose gel electrophoresis, and the size was 700 bp, where M is a nucleic acid marker;

[0020] Figure 4 The nanobody gene product was amplified by the second round of PCR for agarose gel electrophoresis analysis, and the size was about 400 bp;

[0021] Figure 5 The results of double enzyme digestion of nanobody and pMECS phage display vector were analyzed by agarose gel electrophoresis, where M is a nucleic acid marker, lane 1 is the enzyme-digested pMECS vector with a size of 4500 bp, and lane 2 is the nanobody fragment with a size of 400 bp;

[0022] Figure 6 The positive rate of the constructed nanobody phage display library was analyzed by agarose gel electrophoresis, and the nanobody gene inserted into the phage library was identified by bacterial liquid PCR; where M is a marker; 1-48 means picking 48 monoclones, and the size of the positive target fragment is 500bp;

[0023] Figure 7 The indirect ELISA method was used to detect the reactivity of the crude extract of the recombinant nanobody with the FAdV-4Fiber2 protein;

[0024] Figure 8 Agarose gel electrophoresis analysis of double-enzyme digested nanobodies and pCMV-HRP vectors, wherein A is nanobodies Nb12, Nb50, Nb55, Nb61, Nb66, Nb73, Nb75, Nb91, with a size of 400 bp; B is the result of double-enzyme digestion of the recombinant vector pCMV-N1-HRP, with a size of 5000 bp;

[0025] Fig. 9 After the constructed nanobody recombinant expression plasmid was transfected into HEK293T cells, the expression of Fiber2-Nbs-HRP fusion protein in HEK293T cells was analyzed by immunofluorescence, wherein Negative was the pCMV-N1-HRP empty vector;

[0026] Fig.10 ELISA was used to analyze the affinity of Fiber2-Nbs-HRP fusion protein to FAdV-4Fiber2 protein;

[0027] Fig.11 To analyze whether the Fiber2-Nbs-HRP fusion protein binds to FAdV-4 infected LMH cells by immunofluorescence, where the positive is the serum control of FAdV-4 immunized mice;

[0028] Fig.12 For the preliminary screening of Fiber2-Nbs-HRP fusion proteins with neutralizing activity by immunofluorescence, the negative was an irrelevant Nb-HRP control;

[0029] Fig.13 Fenobody-50, -61, -75 and -91 fragments were amplified by PCR for agarose gel electrophoresis analysis, with a size of 800 bp;

[0030] Fig.14The expression of FAdV-4-Fiber 2-Fenobody-50 / 61 / 75 / 91 was identified by SDS-PAGE and Western Blot, wherein M is a protein marker; A is SDS-PAGE identification: Lane 1 is Fenobody-50, with a molecular weight of about 30 kDa; Lane 2 is Fenobody-61, with a molecular weight of about 30 kDa; Lane 3 is Fenobody-75, with a molecular weight of about 30 kDa; Lane 4 is Fenobody-91, with a molecular weight of about 30 kDa; B is Western Blot identification: Lane 1 is Fenobody-50, with a molecular weight of about 30 kDa; Lane 2 is Fenobody-61, with a molecular weight of about 30 kDa; Lane 3 is Fenobody-75, with a molecular weight of about 30 kDa; Lane 4 is Fenobody-91, with a molecular weight of about 30 kDa;

[0031] Fig.15 The toxicity of FAdV-4-Fiber 2Fenobody 50 / 61 / 75 / 91 to LMH cells was analyzed for CCK8, wherein Figure A is the cytotoxicity assay of different protein amounts of Fenobody-50, Figure B is the cytotoxicity assay of different protein amounts of Fenobody-61, Figure C is the cytotoxicity assay of different protein amounts of Fenobody-75, and Figure D is the cytotoxicity assay of different protein amounts of Fenobody-95;

[0032] Fig.16 The half inhibitory concentration (IC) of FAdV-4-Fiber2 Fenobody 50 / 61 / 75 / 91 protein was analyzed by immunofluorescence. 50 );

[0033] Fig.17 For immunofluorescence analysis of the neutralization activity of different concentrations of FAdV-4-Fiber2 Fenobody 75 against FAdV-4;

[0034] Fig.18 To pass TCID 50 Analyze the effect of different concentrations of Fenobody-75 on the titer of FAdV-4 progeny virus;

[0035] Fig.19 Fluorescence quantitative PCR was used to detect the neutralization activity of Fenobody-75 at different concentrations against FAdV-4;

[0036] Fig. 20 Western Blot analysis of the neutralization activity of different concentrations of Fenobody-75 against FAdV-4;

[0037] Fig.21 Survival analysis of FAdV-4 infected chickens treated with Fenobody-75;

[0038] Fig. 22 This is the analysis of viral load in different chicken tissues after FAdV-4-infected chickens were treated with Fenobody-75, where A is the liver, B is the heart, C is the spleen, D is the lung, and E is the kidney;

[0039] Fig.23 Analysis of histopathological lesions in different chickens after FAdV-4 infection was treated with Fenobody-75. DETAILED DESCRIPTION

[0040] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0041] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0042] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0043] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present application description and examples are exemplary only.

[0044] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0045] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are purchased from commercial channels or are publicly available.

[0046] The present invention provides a nanobody that specifically binds to FAdV-4, and its amino acid sequence is as shown in SEQ ID Shown in NO.3.

[0047] The embodiment of the present invention also provides a DNA molecule encoding the nanobody, and its nucleotide sequence is shown in SEQ ID NO.4.

[0048] The present invention also provides a fusion protein, whose amino acid sequence is as shown in SEQ ID Shown in NO.1.

[0049] The embodiment of the present invention also provides a DNA molecule encoding the fusion protein, and its nucleotide sequence is shown as SEQ ID NO.2.

[0050] The embodiment of the present invention also provides a recombinant expression vector, including the DNA molecule.

[0051] In some specific embodiments, the recombinant expression vector is pET-28a-FAdV-4-Fiber2-Fenobody75.

[0052] In some specific embodiments, the preparation method of the recombinant expression vector is: using the nucleotide sequence encoding ferritin as the framework, connecting the nucleotide sequence encoding the nanobody to the C-terminus of ferritin through a GS flexible linker, digesting the obtained fusion sequence with the pET-28a plasmid with restriction endonucleases BamHI and HindⅢ, and then connecting them through T4 ligase, and transforming them into Escherichia coli DH5α competent cells to obtain a recombinant prokaryotic expression plasmid and name it: pET-28a-FAdV-4-Fiber2-Fenobody75.

[0053] In some specific embodiments, the method for preparing the fusion protein is: transforming the constructed pET-28a-FAdV-4-Fiber2-Fenobody75 into Escherichia coli BL21 (DE3) to obtain the recombinant bacteria of BL21 (DE3)-pET-28a-FAdV-4-Fiber2-Fenobody75, inducing expression by IPTG and extracting the protein by ultrasonic fragmentation to obtain the fusion protein.

[0054] The embodiments of the present invention also provide the use of the nanobody, the fusion protein or the recombinant expression vector in the preparation of a drug for preventing and treating FAdV-4 infection.

[0055] An embodiment of the present invention also provides a drug for preventing and treating FAdV-4 infection, comprising the nanobody or the fusion protein.

[0056] Fiber2 is an important structural protein on the surface of FAdV-4, composed of 479 amino acids, which is formed by hydrolysis of precursor proteins. From its N-terminus to its C-terminus, it includes three functional regions: the tail region, the stalk region, and the apical globule region. The tail region is connected to the base of the penton and is an amino acid conserved region; the apical globule region is the functional region for the virus to adsorb host cells. The Fiber2 protein extends outward from the surface of the capsid and plays an important role in virus recognition receptors and virus transmission. In addition, compared with non-pathogenic strains, the Fiber2 protein is a key factor in determining the virulence of different strains of FAdV-4 and is considered to be the main protein for FAdV-4 immune protection. Studies have shown that the Fiber2 protein has subgroup-specific antigenic determinants and can induce the production of major type-specific neutralizing antibodies. The specific neutralizing antibodies induced by the body can effectively resist FAdV-4 infection. Therefore, the Fiber2 protein is an ideal target for the prevention of FAdV-4 infection and the development of therapeutic drugs.

[0057] Ferritin (Fe) is a protein widely found in nature. From bacteria to mammals, the three-dimensional structure of ferritin is highly conserved, including three parts, four bundles of long helices (α-δ) composed of 24 units, one-fifth of short helices (ε) and a long ring composed of β and γ helices. Under a certain pH range, ferritin can self-assemble into spherical nanostructures. Therefore, this property can be used to selectively modify the core and outer surface of ferritin in vitro. Fenobody technology inserts the nanobody sequence into the C-terminus of ferritin to replace its ε helix, and displays the nanobody on the surface of ferritin in the form of 24-mers through the self-assembly property of ferritin. The fusion protein formed by ferritin and nanobody is called Fenobody. Compared with monovalent nanoantibodies, Fenobody is a polymerized nanoantibody with higher affinity and longer half-life than monovalent nanoantibodies, showing great potential in the development of antibody drugs.

[0058] The present invention immunizes Bactrian camels with purified inactivated FAdV-4 to construct a nano-antibody phage display library; then, using purified Fiber2 protein as a coating antigen, a specific nano-antibody against FAdV-4 Fiber2 protein is obtained by phage screening technology. The neutralization activity of the nano-antibody is verified and analyzed by an in vitro neutralization test, and then the Fenobody technology is used to express and prepare anti-FAdV-4 multi-nano-antibody Fenobodies based on the neutralizing active nano-antibody, and the antiviral effect of Fenobodies is analyzed by in vitro and in vivo tests. The Fenobody-75 prepared by the present invention has good preventive and therapeutic effects on FAdV-4 infection in clinical practice, and provides a fast, simple, safe and effective technical means for the prevention and treatment of clinical FAdV-4, which will have a good promotion and application prospect, and has very important practical significance for ensuring the health and rapid development of my country's poultry industry.

[0059] In the embodiment of the present invention, FAdV-4 was isolated and preserved by the Major Animal Disease Pathogen Infection and Pathogenic Mechanism Team of the College of Veterinary Medicine of Northwest Agriculture and Forestry University; Alxa Bactrian camels were purchased from Minqin County, Wuwei City, Gansu Province.

[0060] Example 1

[0061] Screening and preparation of specific nanoantibodies against FAdV-4Fiber2 protein

[0062] (1) Emulsification of immunogens and animal immunization

[0063] After emulsifying the concentrated purified FAdV-4 with an equal volume of complete Freund's adjuvant, 1 mL was injected subcutaneously into the neck of a 4-year-old Alxa Bactrian camel; the remaining 4 times, the purified FAdV-4 was emulsified with an equal volume of incomplete Freund's adjuvant, and immunized once every two weeks, 1 mL each time subcutaneously, for a total of 5 immunizations. 150 mL of camel peripheral blood was collected 7 days after the last immunization.

[0064] Purified FAdV-4 (800 ng / well) was used as the coating antigen, and the anti-FAdV-4 antibody titer in the camel serum after 5 immunizations was detected by indirect ELISA. The results showed that the anti-FAdV-4 antibody titer in the serum was 1:128000 ( Figure 1 ).

[0065] (2) Construction and panning of VHH phage library

[0066] 1) Isolation of peripheral blood lymphocytes

[0067] The peripheral blood lymphocytes collected were separated using Ficoll-Paque PLUS lymphocyte separation solution (Greinerbio-one). After centrifugation, the ring-shaped milky white substance between the plasma and the white transparent lymphocyte separation solution is the lymphocyte ( Figure 2 ). Lymphocytes were aspirated, washed repeatedly with PBS, centrifuged, resuspended and counted, and the number of cells was calculated as 1×10 7 The cells were divided into aliquots and stored at -80℃ for later use.

[0068] 2) Amplification of VHH gene fragments in peripheral blood lymphocytes

[0069] according to Plus Mini RNA Extraction Kit (QIAGEN) was used to extract total RNA (RNA larger than 200 bp) from isolated lymphocytes. III reverse transcriptase (Life technology) was used to synthesize the first-strand cDNA using RNA as a template, and then nested PCR was used to amplify the VHH gene. First, an RNA / primer mixture was prepared, and its system is shown in Table 1.

[0070] Table 1 RNA reverse transcription system

[0071]

[0072] After incubating RNA / primer at 65°C for 5 min, the mixture was immediately placed in an ice water bath for 1 min. Subsequently, a cDNA synthesis mixture was prepared, and its system is shown in Table 2.

[0073] Table 2 cDNA synthesis mixture system

[0074]

[0075] The cDNA synthesis mixture (10 μL) was added to the RNA / primer mixture, mixed, incubated at 50° C. for 50 min, and terminated after incubation at 85° C. for 5 min.

[0076] The VHH gene was amplified by nested PCR using the reverse transcribed cDNA as a template. The primer sequences used are shown in Table 3 below.

[0077] Table 3 Primer sequences for nested PCR amplification of VHH genes

[0078]

[0079] First, primers CALL001 and CALL002 were used to perform the first round of PCR amplification, and the reaction system was shown in Table 4.

[0080] Table 4 First round PCR amplification reaction system

[0081]

[0082] The reaction program was pre-denaturation at 94°C for 5 min; 28 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 45 s; and extension at 72°C for 7 min.

[0083] The PCR product was identified by 1.2% agarose gel electrophoresis, and the results showed that there was a band at the 700 bp and 900 bp positions respectively ( Figure 3 ). The PCR product of 700 bp was recovered using the EasyPure Quick Gel Extraction Kit according to the instructions. The recovered product was then used as a template to perform a second round of PCR amplification using the above-mentioned VHH-FOR and VHH-REV primers. The reaction system is shown in Table 5.

[0084] Table 5 Second round PCR amplification reaction system

[0085]

[0086] The reaction program was pre-denaturation at 94°C for 5 min; 94°C for 30 s, 55°C for 30 s, and 72°C for 30 s, for 18 cycles; and extension at 72°C for 5 min.

[0087] The PCR product was subjected to 1.5% agarose gel electrophoresis, and the results showed that a 400 bp target band was obtained ( Figure 4 ). Then, the PCR product was recovered using the EasyPure Quick Gel Extraction Kit, and the PCR product was the amplified VHH gene.

[0088] 3) Construction of VHH phage display vector

[0089] The above-recovered PCR products and pMECS phage display vector were double-digested with Pst I and Not I at the same time. The specific enzyme digestion system is shown in the following table (Tables 6 and 7).

[0090] Table 6 pMECS phage display vector double restriction enzyme digestion system

[0091]

[0092] Table 7 PCR product double enzyme digestion system

[0093]

[0094] The digestion conditions were 37°C for 16 h. After digestion, the digestion products were recovered using the commercial kit EasyPure Quick GelExtraction Kit, and the digestion results were analyzed by agarose gel electrophoresis to obtain digestion fragments of about 5000 bp and 400 bp, respectively. Figure 5 ).

[0095] The above-recovered PCR digestion product was ligated into the digested phage display vector pMECS using T4 DNA ligase, and the ligation was carried out at 16° C. for 16 h. The ligation system is shown in Table 8.

[0096] Table 8 VHH digestion product and digestion vector pMECS connection system

[0097]

[0098] 4) Preparation of E. coli TG1 competent cells

[0099] E. coli TG1 was cultured to OD 600nm After the pH value is 0.4-0.6, cool in an ice bath, centrifuge and wash three times with pre-cooled 10% glycerol, and finally resuspend the bacteria with 10% glycerol to prepare TG1 competent cells.

[0100] 5) Transformation of TG1 competent cells with ligation products and preparation of phage antibody library

[0101] The ligation product was added to the freshly prepared E. coli TG1 competent cells, mixed and added to the electroporation cup, and the competent cells were electroporated using an Eppendorf electroporator (1.8 kV, 25 μF, 200 Ω, 1 mm). Immediately after the electroporation, SOC medium (2 g tryptone, 0.5 g yeast extract, 0.058 g NaCl and 0.0186 g KCl, dissolved in 96 mL ultrapure water, sterilized by high pressure steam at 121°C for 30 min, and the culture medium was cooled to room temperature, and 2 mL 20% glucose solution, 1 mL 1 M MgCl2 solution and 1 mL 1 M MgSO4 solution were added to resuspend the cells. After shaking culture at 37°C and 120 r / min for 1 h, spread on LB / AMP-GLU large plates (10 g tryptone, 5 g yeast extract, 10 g NaCl and 15 g agar, dissolved in 900 mL ultrapure water, sterilized by high-pressure steam at 121°C for 30 min, and when the culture medium is cooled to about 60°C, add 100 mL 20% glucose solution and 1 mL ampicillin storage solution), culture at 37°C for 6 to 8 h, collect the bacterial lawn with a cell scraper, and add 1 / 3 volume of 50% glycerol to obtain the prepared phage library.

[0102] 6) Determination of phage library diversity and capacity.

[0103] The electroconversion product was diluted 10-fold to 10 -5 Then, the cells were plated on LB / AMP-GLU plates and cultured at 37°C for 12 h. The number of transformants was calculated and the final storage capacity was 1.75×10 7 48 single clones were randomly selected and identified by PCR using the VHH-FOR and VHH-REV primers described in Table 3. Positive clones were identified by agarose gel electrophoresis. The target size was about 400 bp ( Figure 6 ).

[0104] (3) Screening of anti-FAdV4 Fiber2-specific nanobodies

[0105] 1) Rescue of phage library

[0106] The obtained FAdV-4 specific phage display library was inoculated into 2×YT / AMP-GLU (16g tryptone, 10g yeast extract and 5gNaCl, dissolved in 900mL ultrapure water, sterilized by high pressure steam at 121°C for 30min, and after the culture medium was cooled to room temperature, 100mL 20% glucose solution and 1mL ampicillin stock solution were added) culture medium, cultured at 37°C 200r / min, and after the logarithmic phase, M13KO7 helper phage was added, and the culture was allowed to stand at 37°C for 30min. Centrifuged at 2800r / min for 10min, the supernatant was discarded, and the precipitated bacteria were resuspended in 200mL 2×YT / AMP-KAN (16g tryptone, 10g yeast extract and 5gNaCl, dissolved in 1000mL ultrapure water, 1mL kanamycin stock solution and 1mL ampicillin stock solution were added) culture medium, and cultured at 37°C 200r / min for 14h. After centrifugation at 3800 r / min and 4°C for 30 min, collect the supernatant and add 1 / 5 volume of pre-cooled PEG / NaCl solution. Centrifuge at 3800 r / min and 4°C for 30 min, add 1 mL of PBS to resuspend the phage precipitate and fully dissolve it, which is the rescued phage library.

[0107] Take a small amount of phage library solution and dilute it 10 times. -2 , 10 -4 , 10 -6 , 10 -8 , 10 -10 The sample was added to TG1 cells in the logarithmic growth phase and incubated at 37°C for 15 min. The cells were evenly spread on LB / AMP-GLU plates and cultured at 37°C for 8 h. The titer of the recombinant phage was calculated to be 9.1×10 12 PFU / mL.

[0108] 2) Selection of anti-FAdV-4Fiber2 specific recombinant phage

[0109] The purified FAdV-4Fiber2 was coated in an ELISA plate, and PBS was used as a control. The rescued phage library was added to the ELISA plate, incubated at room temperature for 1 hour, and the phage sample was discarded. Then, freshly prepared 0.1M triethylamine was added to each well, and the plate was allowed to stand at room temperature for 10 minutes. The eluate was quickly neutralized with an equal volume of 1M Tris-HCl (pH=7.4).

[0110] Take the eluate and infect 4 mL of TG1 cells in the logarithmic phase, let it stand at 37°C for 30 min, then add 2×YT / AMP-GLU medium and culture at 37°C and 200 r / min until OD 600nm The above operation was repeated to rescue the phage library, and then the second and third rounds of panning were performed, and the phage titer was measured in each round. The results showed that after three rounds of panning, the P / N value increased from 1 to 570, proving that the anti-FADV-4Fiber 2 phage was effectively enriched (Table 9).

[0111] Table 9 Enrichment of anti-FAdV-Fiber2 protein specific phage

[0112]

[0113] (4) Preparation of crude extracts of recombinant nanobodies

[0114] 96 single colonies were randomly selected from the plate with the third round of eluted phage titer, marked 1-96 in sequence, inoculated into a 96-well plate, LB / AMP-GLU medium was added to each well, and cultured at 37°C, 200 r / min for 8 h.

[0115] 10 μL of culture medium was aspirated from each clone and inoculated into 1 mL of TB medium. The culture was then cultured in a 24-well culture plate at 37°C and 200 rpm until the OD value of the clone reached the logarithmic phase. 600nm The pH value was 0.6-0.8, and IPTG with a final concentration of 0.1 mM was added to each well to induce expression. The expressed bacteria were centrifuged and precipitated, and then frozen and thawed three times, centrifuged at 3500 r / min and 4°C for 15 min, and the supernatant was collected as the crude extract of soluble recombinant nanoantibodies.

[0116] (5) Indirect ELISA to detect the specific binding of recombinant nanobody crude extract to FAdV-4Fiber2 protein

[0117] The purified FAdV-4Fiber2 protein was coated on the ELISA plate, and an irrelevant E. coli was used as a negative control. The crude extract of the soluble recombinant nanobody was diluted 1:1 with 2.5% skim milk powder and added to the ELISA plate, and incubated at room temperature for 1 hour. Dissolve in PBS'T (8.5g NaCl, 3.352g Na2HPO4·12H2O, 0.286g NaH2PO4·2H2O in deionized water) and dilute to 1000mL, pH 7.2-7.4, add 0.5mL eluent (PBS'T containing 0.05% Tween-20) to wash the plate, add commercial mouse anti-HA-tag antibody (Beijing Quanshijin Biotechnology Co., Ltd.), incubate at room temperature for 1h. Then add commercial HRP-labeled goat anti-mouse IgG (Beijing Boosun Biotechnology Co., Ltd.) and incubate at room temperature for 1h. Add TMB colorimetric solution (Solarbio) and color at room temperature in the dark for 15min, terminate the reaction with 3M concentrated sulfuric acid, and read OD with an automatic microplate reader. 450nm The results showed that 82 of the 96 crude extracts could specifically bind to the FAdV-4Fiber2 protein ( Figure 7 ). The positive strains were sequenced, and the results showed that 8 anti-FAdV-4Fiber 2 protein nanoantibodies were successfully screened and obtained, which were named Fiber2-Nb12, Fiber2-Nb50, Fiber2-Nb55, Fiber2-Nb61, Fiber2-Nb66, Fiber2-Nb73, Fiber2-Nb75, and Fiber2-Nb91.

[0118] Example 2

[0119] Expression and preparation of FAdV-4Fiber2 nanobody and horseradish peroxidase (HRP) fusion protein

[0120] (1) Construction of recombinant eukaryotic expression vector of nanobody and HRP fusion protein

[0121] The eukaryotic expression vector pCMV-N1-HRP (containing His and HA tags) and the product obtained by PCR containing the encoding nanobody were double-digested using PstI and NotI endonucleases. The results of agarose gel electrophoresis showed that the target bands of about 5000 bp and 400 bp were successfully obtained, respectively. The VHH gene obtained by enzyme digestion was then ligated to the pCMV-N1-HRP vector using T4 ligase to obtain a recombinant positive plasmid expressing the nanobody and HRP fusion protein, named pCMV-N1-Fiber2-Nbs-HRP ( Figure 8 ).

[0122] (2) Expression and preparation of nanobody and HRP fusion protein

[0123] The successfully constructed pCMV-N1-Fiber2-Nbs-HRP positive plasmid was After the medium and PEI transfection reagent were mixed evenly, they were added to HEK293T cells and cultured at 37°C, 5% CO2 for 48 hours, and the supernatant was collected. The transfected HEK293T cells were fixed with 4% paraformaldehyde, incubated with commercial His monoclonal antibody (Quanshijin Biotechnology Co., Ltd.) at room temperature, and then incubated with FITC-labeled goat anti-mouse IgG. Immunofluorescence was used to detect whether the recombinant fusion protein was expressed in HEK293T cells; the results showed that the HEK293T cells transfected with the positive plasmid emitted green fluorescence, proving that the fusion protein was successfully expressed ( Fig. 9 ).

[0124] Example 3

[0125] Preliminary screening of FAdV-4 neutralizing nanoantibodies

[0126] (1) ELISA verification of the specific binding of nanoantibodies and HRP fusion proteins to FAdV-4Fiber2 protein

[0127] HEK293T cells were transfected with pCMV-N1-Fiber2-Nbs-HRP positive plasmid and cultured at 37°C, 5% CO2 for 48 hours, and the supernatant was collected. The collected supernatant was diluted in proportion (1:10, 1:50, 1:100, 1:500, 1:1000, 1:2000) and directly added to the ELISA plate coated with FAdV-4Fiber 2 protein (400ng / well). After TMB color development, the results showed that except for Nb55, which did not bind to Fiber2 protein, Nb-12, -50, -61, -66, -73, -75 and -91 all bound to FAdV-4Fiber2 protein with high affinity ( Fig.10 ).

[0128] (2) IFA identification of the binding of nanoantibodies to FAdV-4

[0129] LMH cells were seeded in 24-well plates (6×10 4cells / well) and cultured in a 37°C, 5% CO2 incubator. When the cell density reached about 75%, FAdV-4 was inoculated with 0.1 MOI and cultured in a 37°C, 5% CO2 incubator for 48 hours. The culture medium was discarded, 400 μL of 70% ice ethanol was added to each well, and fixed at 4°C for 30 minutes. The fixative was discarded, 400 μL of 1% BSA was added to each well, and blocked at 37°C for 1 hour. 200 μL of FAdV-4-Fiber2-Nbs were added respectively, and FAdV-4 positive mouse serum was used as a control (1:200 dilution), PBS was used as a negative control, and incubated at 4°C overnight, and commercial His monoclonal antibody (Quanshijin Biotechnology Co., Ltd.) was incubated at room temperature, and then FITC-labeled goat anti-mouse IgG was incubated, and observed under a fluorescence microscope to identify whether FAdV-4-Fiber 2-Nbs binds to FAdV-4. IFA results showed that FAdV-4-Fiber 2-Nb12, -50, -61, -66, -73, -75 and -91 all bound to FAdV-4 ( Fig.11 ).

[0130] (3) IFA preliminary screening of nanoantibodies with the ability to neutralize FAdV-4

[0131] LMH cells were seeded in 24-well plates (6×10 4 cells / well) and cultured in a 37°C, 5% CO2 incubator. When the cell density reached about 75%, the FAdV-4-Fiber2-Nbs screened above were incubated with 0.1MOI of FAdV-4 at 4°C overnight and then inoculated into LMH cells. 24 hours after infection, the culture medium was discarded, 400μL of 70% ice ethanol was added to each well, and fixed at 4°C for 30 minutes. FAdV-4 positive mouse serum (1:200 dilution) was used as the primary antibody, incubated at room temperature for 1 hour, FITC-Goat@MouseIgG (1:400 dilution) was used as the secondary antibody, incubated at room temperature for 1 hour, and finally 200μL of DAPI (1:600 ​​dilution) was added to each well and incubated at room temperature for 10 minutes. Observed under an inverted fluorescence microscope, the fewer cells showing green fluorescence, the stronger the neutralizing activity of the nanobody. The results showed that the four nanoantibodies FAdV-4-Fiber2-Nb50, -61, -75 and -91 had strong in vitro virus neutralization effects ( Fig.12 ).

[0132] Example 4

[0133] Preparation of anti-FAdV-4 fenobody and analysis of its antiviral activity in vitro

[0134] (1) Construction of recombinant prokaryotic expression vector of nanobody and ferritin fusion protein

[0135] Primers were designed based on the gene sequences encoding nanobodies and ferritin. The primer sequences are shown in Table 10. The gene sequences of the four strains of nanobodies that neutralize FAdV-4 were connected to the ferritin sequences respectively using GS flexible linker. The obtained fusion gene sequences encoding nanobodies and ferritin were then double-digested with the pET-28a vector by HindIII and BamH I. The digestion system is shown in Table 11. The gene sequence obtained by digestion was then connected to the vector sequence using T4 ligase, and the vector construction was successfully identified by bacterial liquid PCR ( Fig.13 ), which were named pET-28a-FAdV-4-Fiber 2-Fenobody-50, -61, -75 and -91.

[0136] Table 10 Amplification of Fenobody Primer Sequences

[0137]

[0138] Table 11 pET-28a-FAdV-4-Fiber2-Fenobodies connection system

[0139]

[0140] (2) Expression and purification of Fenobody50, -61, -75 and -91

[0141] The pET-28a-FAdV-4-Fiber2-Fenobody50, -61, -75 and -91 positive plasmids were transformed into Escherichia coli BL21 (DE3) to obtain recombinant expression bacteria of different Fenobodies. The cells were cultured at 37°C and 200 r / min until the logarithmic phase (OD 600nm 0.6-0.8), add IPTG with a final concentration of 0.1mM to induce expression, continue to culture at 37℃ for 8h, collect the bacterial solution, and use Ni column to purify after ultrasonic disruption. After SDS-PAGE and Western Blot analysis, the expected 30kDa target band ( Fig.14 ).

[0142] (3) Cytotoxicity analysis of Fenobody50, -61, -75 and -91

[0143] LMH cells were seeded in 96-well plates (1.5×10 4cells / well) and cultured in a 37°C, 5% CO2 incubator. Fenobody 50, -61, -75 and -91 purified in Example 4 (2) were diluted in F12 medium to a final concentration of 1 mg / mL, 10 mg / mL, 20 mg / mL and 30 mg / mL, respectively. When the cell density reached 90%, PBS (K + ) After washing the cells three times, add the diluted Fenobody50, -61, -75 and -91, set up 4 replicate wells for each dilution, and set up 4 blank controls. After incubation at 37°C in the dark for 1 hour, discard the Fenobodies, add 100 μL 2% F12 medium to each well, and continue to culture for 36 hours. Discard the medium, add 10 μL CCK-8 solution to each well, and incubate at 37°C in the dark for 1 hour. Read the OD with a microplate reader 450nm The cytotoxicity of Fenobody50, -61, -75 and -91 was analyzed. The results showed that when pET28a-FAdV-4-Fiber2-Fenobody50, -61, -75 and -91 were added in the range of 0-30 μg, there was no significant effect on the activity of LMH cells ( Fig.15 ).

[0144] (4) Fenobody 50, -61, -75 and -91 neutralize FAdV-4IC 50 Determination of

[0145] Fenobody 50, -61, -75 and -91 purified in Example 4 (2) were serially diluted from 20 mg / mL using F12 medium (2 -1 -2 -10 ) were incubated with 0.1 MOI of FAdV-4 at 4°C overnight and then added to LMH cells. After 24 h, the IC values ​​of Fenobody50, -61, -75 and -91 proteins were detected. 50 The results showed that the IC of Fenobody75 50 0.6166 μg / mL, Fenobody50, -61 and -91 had no neutralization effect on FAdV-4 ( Fig.16 ).

[0146] (5) Analysis of the antiviral activity of Fenobody75 protein in vitro

[0147] 0.1 μg, 1 μg and 10 μg of Fenobody75 were incubated with 0.1 MOI of FAdV-4 at 4°C overnight to infect LMH cells. After 24 h, the supernatant was collected and TCID 50The results of IFA showed that, compared with the negative group (NDV-VII-Fenobody71 incubation group), the number of infected cells decreased with the increase of Fenobody75 dose, and the effect was dose-dependent ( Fig.17 );TCID 50 The results showed that as the dose of Fenobody75 increased, the titer of FAdV-4 virus gradually decreased in a dose-dependent manner ( Fig.18 ); The expression of FAdV-4Hexon protein was detected by Western Blot, and the FAdV-4Hexon band was scanned in grayscale. The results showed that with the increase of Fenobody75 dose, the expression of FAdV-4Hexon protein gradually decreased in a dose-dependent manner ( Fig.19 ). The above results indicate that Fenobody75 protein has significant in vitro neutralization activity against FAdV-4.

[0148] The amino acid sequence of Fenobody75 is shown in SEQ ID NO.1:

[0149] SEQ ID NO.1:MLSERMLKALNDQLNRELYSAYLYFAMAAYFEDLGLEGFANWMKAQAEEE IGHALRFYNYIYDRNGRVELDEIPKPPKEWESPLKAFEAAYEHEKFISKSIYELAALAEEEKDYSTRAFLEWFINEQVEEEASVKKILDKLKFAKDGGGGSGGGGSGGGGSESGGGS VQTGGSLRLSCVVSGYSTMPYYMTWFRQSPGKEREGVSNIISHDADTFYAAPVKGRFTISHDMTENTLYLQMNDLRPEDTGLYYCKAVVSQCWNWLSQEAYEYWGQGTQVTVSSAA.

[0150] The nucleotide sequence encoding Fenobody75 is shown in SEQ ID NO.2:

[0151] SEQ ID NO.2: ATGCTGAGCGAACGCATGCTGAAGGCTTTAAACGACCAGCTGAATCGTG AACTGTACAGCGCCTATTTATACTTCGCCATGGCCGCCTATTTTGAAGATCTGGGTTTAGAGGGTTTCGCCAATTGGATGAAAGCCCAAGCTGAAGAAGAGATCGGTCATGCTTTACGCTTCTACAACTATATCTATGATCGCAACGGCCGCGTGGAACTGGACGAAATTCCGAAACCGCCGAAAGAGTGGGAAAGCCCGCTGAAAGCCTTTGAGGCCGCCTACGAGCACGAAAAATTCATCAGCAAAAGCATTTATGAACTGGCCGCTTTAGCCGAGGAAGAAAAAGACTATAGCACCCGCGCCTTTCTGGAGTGGTTTATCAACGAGCAAGTTGAAGAAGAAGCCAGCGTGAAGAAAATTTTAGACAAACTGAAATTTGCCAAGGACGGCGGTGGAGGCAGTGGCGGTGGAGGCAGTGGCGGTGGAGGCAGTGAGTCTGGGGGAGGCTCGGTGCAAACTGGAGGGTCTCTGAGACTGTCCTGTGTAGTATCTGGTTATAGCACAATGCCATACTACATGACATGGTTCCGCCAAAGTCCAGGCAAGGAGCGCGAGGGAGTCTCAAATATTATCAGTCATGATGCGGACACATTCTATGCCGCGCCGGTGAAGGGCCGATTCACCATTTCCCATGACATGACCGAGAACACCCTGTATCTCCAAATGAACGACCTGAGACCTGAAGACACTGGCTTGTACTACTGTAAAGCAGTTGTTTCACAGTGTTGGAACTGGCTGTCCCAAGAGGCGTATGAATACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCAGCGGCCGC。

[0152] The amino acid sequence of the Fiber2-Nb75 antibody is shown in SEQ ID NO.3:

[0153] SEQ ID NO. 3: QVQLQESGGGSVQTGGSLRLSCVVSGYSTMPYYMTWFRQSPGKEREGVSN IISHDADTFYAAPVKGRFTISHDMTENTLYLQMNDLRPEDTGLYYCKAVVSQCWNWLSQEAYEY WGQGTQVTVSSAA.

[0154] The nucleotide sequence encoding the Fiber2-Nb75 antibody is shown in SEQ ID NO.4:

[0155] SEQ ID NO.4: CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTCGGTGCAAACTGGAGGG TCTCTGAGACTGTCCTGTGTAGTATCTGGTTATAGCACAATGCCATACTACATGACATGGTTCCGCCAAAGTCCAGGCAAGGAGCGCGAGGGAGTCTCAAATATTATCAGTCATGATGCGGACACATTCTATGCCGCGCCGGTGAAGGGCCGATTCACCATTTCCCAT GACATGACCGAGAACACCCTGTATCTCCAAATGAACGACCTGAGACCTGAAGACACTGGCTTGTACTACTGTAAAGCAGTTGTTTCACAGTGTTGGAACTGGCTGTCCCAAGAGGCGTATGAATACTGGGGCCAGGGGGACCCAGGTCACCGTCTCCTCAGCGGCCGC.

[0156] The amino acid sequence of ferritin is shown in SEQ ID NO.5:

[0157] SEQ ID NO.5: MLSERMLKALNDQLNRELYSAYLYFAMAAYFEDLGLEGFANWMKAQAEEE IGHALRFYNYIYDRNGRVELDEIPKPPKEWESPLKAFEAAYEHEKFISKSIYELAALAEEEKDYSTRAFLEWFINEQVEEEASVKKILDKLKFAKD.

[0158] The nucleotide sequence encoding ferritin is shown in SEQ ID NO.6:

[0159] SEQ ID NO.6: ATGCTGAGCGAACGCATGCTGAAGGCTTTAAACGACCAGCTGAATCGTG AACTGTACAGCGCCTATTTATACTTCGCCATGGCCGCCTATTTTGAAGATCTGGGTTTAGAGGGTTTCGCCAATTGGATGAAAGCCCAAGCTGAAGAAGAGATCGGTCATGCTTTACGCTTCTACAACTATATCTATGATCGCAACGGCCGCGTGGAACTGGACGAAATTCCGAAACCGCCGAAAGAGTGGGGAAA GCCCGCTGAAAGCCTTTGAGGCCGCCTACGAGCACGAAAAATTCATCAGCAAAAGCATTTATGAACTGGCCGCTTTAGCCGAGGAAGAAAAAGACTATAGCACCCGCGCCTTTCTGGAGTGGTTTATCAACGAGCAAGTTGAAGAAGAAGCCAGCGTGAAGAAAATTTTAGACAAACTGAAATTTGCCAAGGAC.

[0160] Effect example

[0161] Analysis of the effect of Fenobody75 protein in preventing and treating FAdV-4 virus attack

[0162] Based on the purified Fenobody75 protein obtained in Example 4(2), an animal challenge therapy experiment was conducted. The experimental groups are as follows:

[0163] Thirty-six SPF chickens were randomly divided into 6 groups, namely, PBS control group, virus-only group, Fenobody injection group, prevention group, virus-1h treatment group and virus-24h treatment group. The chickens in each group were kept in isolation. 5.16 TCID 50FAdV-4; PBS control group chickens were injected with 2mL PBS in the chest muscle; the prevention group was injected with 10mg / kg Fenobody75 in the chest muscle 1h before the challenge, and the treatment group 1h after the challenge was injected with 10mg / kg Fenobody75 in the chest muscle 1h, 12h, 24h and 48h after the challenge; the treatment group 24h after the challenge was injected with 10mg / kg Fenobody75 in the chest muscle 24h, 36h, 48h and 72h after the challenge; the Fenobody injection control group and the treatment group 1h after the challenge were injected with 10mg / kg Fenobody75 in the chest muscle at the same time to evaluate whether Fenobody has a toxic effect on the chicken body. The animal grouping is shown in Table 12 below, and the in vivo test of animal Fenobody75 is shown in Table 13.

[0164] Table 12 Grouping of Fenobody75 in vivo challenge protection test

[0165]

[0166]

[0167] Neutralization protection efficiency of Fenobody75. The experimental results showed that all the experimental chickens in the challenge group died 6 days after the challenge, with a mortality rate of 100%, indicating that the challenge was successful. In the 1h challenge group, one chicken died on the 4th and 5th days after the challenge, respectively, and the survival rate of the chickens was 66%. In the 24h challenge group, one chicken died on the 3rd and 4th days after the challenge, respectively, and the survival rate of the chickens was 66%; no chickens died in the PBS group, the Fenobody control group, and the Fenobody prevention group, and the survival rate was 100% ( Fig. 20 ). After 7 days of feeding, the chickens were uniformly killed, and two samples of heart, spleen, liver, lung and kidney were collected for viral load detection and pathological histological analysis. The results of tissue and organ virus quantification showed that FAdV-4 was detected in the heart, spleen, liver, lung and kidney of the chickens in the challenge group; the virus was only detected in the liver in each treatment group; FAdV-4 was only detected in the kidney in the prevention group, and the load was significantly lower than that in the challenge group ( Fig.21 HE section staining results showed that the heart, lungs, liver, spleen and kidneys of the chickens in the challenge group showed obvious pathological damage, and the histopathological damage of the chickens in the Fenobody75 treatment groups and the prevention group was greatly alleviated, among which the prevention group and the 1-hour challenge group showed the lightest pathological damage ( Fig. 22 ).

[0168] In summary, the Fenobody75 prepared by the present invention has an obvious neutralizing effect on FAdV-4 in vitro experiments, and the results of in vivo challenge treatment experiments show that injection of Fenobody75 can effectively improve the survival rate of FAdV-4 infected chickens and reduce the viral load and pathological damage of various tissues and organs. Therefore, the Fenobody75 provided by the present invention can effectively prevent and treat FAdV-4 infection, reduce the economic losses caused by FAdV-4 to the poultry industry, and has significant economic value and application market.

[0169] Obviously, the above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the implementation methods of the present invention. For ordinary technical users in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. A nanobody that specifically binds to FAdV-4, characterized in that Its amino acid sequence is shown in SEQ ID Shown in NO.

3.

2. A DNA molecule encoding a nanobody according to claim 1, characterized in that: Its nucleotide sequence is shown in SEQ ID NO.

4.

3. A fusion protein, characterized in that Its amino acid sequence is shown in SEQ ID Shown in NO.

1.

4. A DNA molecule encoding the fusion protein according to claim 3, characterized in that: Its nucleotide sequence is shown in SEQ ID NO.

2.

5. A recombinant expression vector, characterized in that: Comprising the DNA molecule as described in claim 4.

6. The recombinant expression vector according to claim 5, characterized in that The recombinant expression vector is pET-28a-FAdV-4-Fiber2-Fenobody75.

7. Use of the nanobody according to claim 1, the fusion protein according to claim 3 or the recombinant expression vector according to claim 5 in the preparation of a drug for preventing and treating FAdV-4 infection.

8. A drug for preventing and treating FAdV-4 infection, characterized in that: Comprising the nanobody according to claim 1 or the fusion protein according to claim 3.

Citation Information

Patent Citations

  • Monoclonal antibody of Penton protein of FAdV-4, hybridoma cell strain secreted by monoclonal antibody and application of hybridoma cell strain

    CN116716258A

  • Serum type 4 fowl adenovirus nano antibody as well as preparation method and application thereof

    CN116813756A